Literature DB >> 11925138

PTEN mutations in uterine sarcomas.

F Amant1, M de la Rey, C M Dorfling, L van der Walt, G Dreyer, L Dreyer, I Vergote, B G Lindeque, E J Van Rensburg.   

Abstract

OBJECTIVE: Uterinesarcomas comprise three main types: carcinosarcomas, leiomyosarcomas, and endometrial stromal sarcomas. Carcinosarcomas are highly aggressive neoplasms with a biphasic histology of carcinomatous and sarcomatous elements. It is now generally accepted that carcinosarcomas are biphasic tumors that have to be regarded as endometrial carcinomas where metaplasia occurs. Mutations of the PTEN tumor suppressor gene, located on 10q23, play a significant role in the pathogenesis of the endometrioid type of endometrial carcinoma. Loss of heterozygosity of chromosome 10q has been reported in uterine leiomyosarcoma. Since little is known about the molecular pathobiology, our goal was to investigate the potential role of the PTEN gene in the carcinogenesis of uterine sarcomas.
METHODS: We examined 21 carcinosarcomas, 21 leiomyosarcomas, and 5 endometrial stromal sarcomas using exon-by-exon polymerase chain reaction-single-strand conformation polymorphism analysis.
RESULTS: Overall 8.5% (4/47) of uterine sarcomas were found to harbor somatic PTEN mutations. Of these, approximately 17% (3/18) were carcinosarcomas with endometrioid-type carcinoma components and approximately 5% (1/21) were leiomyosarcomas. No mutations were detected in carcinosarcomas with nonendometrioid carcinoma components (0/3) and in endometrial stromal sarcomas (0/5).
CONCLUSIONS: These data suggest that intragenic PTEN mutations are involved in the genesis of uterine carcinosarcomas with endometrioid-type carcinoma components but rarely contribute to the pathobiology of uterine leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925138     DOI: 10.1006/gyno.2002.6601

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Authors:  Kari J Brewer Savannah; Elizabeth G Demicco; Kristelle Lusby; Markus Ph Ghadimi; Roman Belousov; Eric Young; Yiqun Zhang; Kai-Lieh Huang; Alexander J Lazar; Kelly K Hunt; Raphael E Pollock; Chad J Creighton; Matthew L Anderson; Dina Lev
Journal:  Clin Cancer Res       Date:  2012-07-20       Impact factor: 12.531

2.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

3.  Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma.

Authors:  Jasmine H Francis; Ruth A Kleinerman; Johanna M Seddon; David H Abramson
Journal:  Gynecol Oncol       Date:  2011-10-23       Impact factor: 5.482

4.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

5.  Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma.

Authors:  Allie H Grossmann; Lester J Layfield; R Lor Randall
Journal:  Sarcoma       Date:  2012-02-15

6.  Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.

Authors:  A Coosemans
Journal:  Facts Views Vis Obgyn       Date:  2011

7.  Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.

Authors:  Siân Jones; Nicolas Stransky; Christine L McCord; Ethan Cerami; James Lagowski; Devon Kelly; Samuel V Angiuoli; Mark Sausen; Lisa Kann; Manish Shukla; Rosemary Makar; Laura D Wood; Luis A Diaz; Christoph Lengauer; Victor E Velculescu
Journal:  Nat Commun       Date:  2014-09-19       Impact factor: 14.919

Review 8.  Soft Tissue Sarcoma Cancer Stem Cells: An Overview.

Authors:  Katia C Genadry; Silvia Pietrobono; Rossella Rota; Corinne M Linardic
Journal:  Front Oncol       Date:  2018-10-26       Impact factor: 6.244

9.  microRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: a preliminary report.

Authors:  Magdalena Kowalewska; Elwira Bakula-Zalewska; Magdalena Chechlinska; Krzysztof Goryca; Anna Nasierowska-Guttmejer; Anna Danska-Bidzinska; Mariusz Bidzinski
Journal:  Tumour Biol       Date:  2013-04-05

10.  Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.

Authors:  Eucharist H S Kun; Yvonne T M Tsang; Sophia Lin; Sophia Pan; Tejas Medapalli; Anais Malpica; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.